Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

EOVIST

GADOXETATE DISODIUM

Standard Dose
1.8143GM/10ML (181.43MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview EOVIST is listed in Drugs@FDA under application 022090 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient GADOXETATE DISODIUM Form and strength SOLUTION;INTRAVENOUS - 1.8143GM/10ML (181.43MG/ML) Sponsor BAYER HLTHCARE Submission history Latest submission status date: 2026-02-13 00:00:00.

Structured Monograph

Clinical summary

Approval overview EOVIST is listed in Drugs@FDA under application 022090 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient GADOXETATE DISODIUM Form and strength SOLUTION;INTRAVENOUS - 1.8143GM/10ML (181.43MG/ML) Sponsor BAYER HLTHCARE Submission history Latest submission status date: 2026-02-13 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Prescription
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
EOVIST (GADOXETATE DISODIUM) | Drug Monograph | MedicHelpline